Northwell Health Performs First Commercial Vanquish Water Vapor Ablation Procedure in New York
Event summary
- Northwell Health performed the first commercial Vanquish Water Vapor Ablation procedure in New York on August 5, 2026.
- The procedure was conducted by Dr. Samir S. Taneja, chairman of the Department of Urology at Northwell Health.
- The Vanquish System received FDA 510(k) clearance in late 2025 and is designed for minimally invasive prostate tissue ablation.
- The VAPOR 2 study showed a 91% elimination rate of targeted MRI-visible clinically significant disease in 110 patients.
The big picture
This milestone marks the first commercial use of the Vanquish System outside of a clinical trial, signaling a potential shift in prostate cancer treatment towards minimally invasive options. The positive outcomes from the VAPOR 2 study and the involvement of a leading urologist like Dr. Taneja could accelerate adoption among other major healthcare providers.
What we're watching
- Adoption Pace
- How quickly the Vanquish System will be adopted by other major urology groups across the U.S.
- Regulatory Clarity
- Whether the FDA will provide further guidance on long-term outcomes for prostate cancer treatment using the Vanquish System
- Market Expansion
- The pace at which Francis Medical can expand its commercial reach beyond New York.
Related topics